Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

FDA approves Flexion’s knee pain drug, shares surge

Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its injectable drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain, sending its shares soaring 18 percent.

The approval comes at a time when U.S. federal authorities are implementing a slew of measures to cut down the supply of opioid painkillers amid their continuous abuse, with President Donald Trump in August declaring the opioid epidemic a national emergency.

The drug would be priced at about $500 for a single injection, Flexion’s CEO Mike Clayman told Reuters, adding that it would be launched in the coming month.

Zilretta, a modified formulation of a commonly used corticosteroid, could bag potential peak sales of more than $750 million according to Northland Capital Markets analyst Carl Byrnes.

“Zilretta … has the potential to be a gamechanger in osteoarthritis knee pain treatment,” Wells Fargo analyst David Maris said in a client note ahead of the regulator’s decision.

Osteoarthritis knee pain is a degenerative joint disease that affected more than 14 million Americans in 2015.

Source: CNBC

Add Comment

Your email address will not be published. Required fields are marked *